Fig. 7. Effect of recombinant IP-10 treatment on YFV-17D pathogenesis in mice. (a) Survival of YFV-17D-infected mice after treatment with IP-10. IFNAR^−/− mice were intramuscularly inoculated with 10⁷ p.f.u. YFV-17D and at −1, 1, 3 and 5 days p.i. 100 ng recombinant IP-10 or PBS was administered intraperitoneally. Disease onset was monitored and data are presented as the percentage without disease. Results are from 14 IP-10-treated mice and 35 PBS-treated mice. Statistically significant differences between survival of IP-10 and PBS-treated mice were found, indicated by an asterisk ( P<0.05, Mantel–Cox test). (b) Percentages of mice displaying no clinical signs of disease, neurotropic disease or viscerotropic disease in YFV-17D-infected mice treated with PBS or IP-10. Statistically significant differences were observed between the percentages of mice with viscerotropic disease in the IP-10-treated group as compared with the PBS-treated group (50 versus 17 %, respectively; P<0.001, χ² test). ns, Not significant.